Hemorheologic Approach in the Treatment of Diabetic Foot Ulcers

Abstract

Pentoxifylline, a new trisubstituted methyxanthine derivative, is the most well known of a new group of hemorheologic agents. It has been shown to im prove hemorheologic abnormalities associated with diabetes and atherosclero sis. The authors examined the role of pentoxifylline in the treatment of diabetic foot ulcers. Forty diabetic patients with foot ulcerations were included in the study, 20 of whom received conventional therapy and 20 received pentoxifylline (400 mg three times a day) in addition. Healing of ulcers after eight weeks of treatment was significantly higher in those on pentoxifylline, and the patients needed less multilating surgery. Administration of pentoxifylline in addition to conventional therapy was significantly superior in the management of diabetic foot ulcers.

Get full access to this article

View all access options for this article.

References

Malins JM : In: Clinical Diabetes Mellitus. London: Eyre and Spotswoode, 1968.

Reid HL , Dormandy JA , Barnes AJ , et al: Impaired red cell deformability in peripheral vascular disease . Lancet 1:666-668, 1979.

Schmid-Schoenbein H. : Blood rheology and physiology of microcirculation. Rev Clin Lab 1 (Suppl 1): 13-16, 1981.

Accetto B. : Beneficial hemorheological therapy of chronic peripheral arterial disorders with pentoxifylline: Results of double-blind study versus vasodilator—nylidrin . Am Heart J 103:864-869, 1982.

Angelkort B. , Pirnay D. , Kiesewetter H. , et al: Hemodilution and pentoxifylline effects on muscle blood flow and blood fluidity in chronic arterial disease. Vasc Med 1:150-157, 1983.

Aviado DM , Dettelbach HR : Pharmacology of pentoxifylline, a hemorheologic agent for the treatment of intermittent claudication. Angiology 35:407-417, 1984.

Chopra HK , Chopra KL , Aggarwal KK , et al: Pentoxifylline (Trental)—a new drug for the treatment of peripheral chronic occlusive arterial disease. J Med 19:89-107, 1988.

Weitgasser H. : The use of pentoxifylline (Trental 400) in the treatment of leg ulcers: Results of a double-blind trial. Pharmatherapeutica 3 (suppl 1): 143-151, 1983.

Wagner FW : Algorithms of diabetic foot care. In: The Diabetic Foot, ed by Levin ME , O'Neal FW. St. Louis: CV Mosby, 1983, p 291.

10.

Schwartz RW , Logan NM , Johnson PJ , et al: Pentoxifylline increases extremity blood flow in diabetic atherosclerotic patients. Arch Surg 124:434-437, 1989.

11.

Porter JM , Cutler BS , Lee BY , et al: Pentoxifylline efficacy in the treatment of intermittent claudication: Multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 104:66-72, 1982.

12.

Schubotz R. : Double-blind trial of pentoxifylline in diabetics with peripheral vascular disorders. Pharmatherapeutica 1:172-179, 1976.

13.

Roeren T. , LeVeen RF , Nugent L. : Photoplethysmographic documentation of improved microcirculation after pentoxifylline therapy. Angiology 39:929-933, 1988.

14.

Muller R. : On the therapy of disturbances of blood fluidity. Angiology 36:226, 1985.

15.

Jarrett Pem , Moreland M. , Browse NL : The effect of pentoxifylline on fibrinolytic activity and plasma fibrinogen levels. Curr Med Res Opin 4:492-496, 1977.